(Reuters) - The U.S. Food and Drug Administration on Wednesday approved GlaxoSmithKline's (L:GSK) experimental treatment for a common form of blood cancer. GSK's belantamab...
LONDON (Reuters) - An independent panel to the U.S. Food and Drug Administration on Tuesday voted in favour of approving GlaxoSmithKline's (L:GSK) experimental treatment for a...
(Reuters) - GlaxoSmithKline (L:GSK) said on Monday it had applied for U.S. approval for its experimental multiple myeloma drug that showed meaningful response in nearly a third of...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Summary | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 8,846.00 | 8,850.00 | 8,674.00 | +38.0 | +0.43% | 157.62K | London | |||
| 109.44 | 110.82 | 108.96 | -1.00 | -0.91% | 45.55M | London | |||
| 175.72 | 181.70 | 172.16 | -7.20 | -3.94% | 29.36M | London | |||
| 63.80 | 63.80 | 62.20 | +3.60 | +5.98% | 104.68K | London | |||
| 197.85 | 199.95 | 197.65 | -1.40 | -0.70% | 4.71M | London | |||
| 88.50 | 88.50 | 88.50 | +0.50 | +0.57% | 321.33K | London | |||
| 199.46 | 200.30 | 197.36 | +1.64 | +0.83% | 29.56M | London | |||
| 5,002.00 | 5,089.00 | 4,989.00 | -36.0 | -0.71% | 2.14M | London | |||
| 1,140.00 | 1,144.00 | 1,127.00 | +11.00 | +0.97% | 1.02M | London | |||
| 593.80 | 597.60 | 588.40 | -5.60 | -0.93% | 5.10M | London | |||
| 58.38 | 58.88 | 58.04 | -0.10 | -0.17% | 15.23M | London | |||
| 1,529.00 | 1,530.00 | 1,512.00 | +8.50 | +0.56% | 922.66K | London | |||
| 8,699.00 | 8,768.00 | 8,667.00 | -96.0 | -1.09% | 1.05M | London | |||
| 181.75 | 183.60 | 180.35 | -2.45 | -1.33% | 3.44M | London | |||
| 7,928.00 | 7,956.00 | 7,802.00 | +60.0 | +0.76% | 203.15K | London |
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.